In another study, Tan et al. synthesized CLT1 peptide loaded MRI contrast agents for targeting fibrin-fibronectin complexes, the following in vivo studies demonstrated CLT1 loaded contrast agents provided excellent MRI contrast enhancement in PCa tumor-bearing mice [20]. The gene discussed is FN1; the disease is posterior cortical atrophy.